Adsorption of chitosan on PET films monitored by quartz crystal microbalance

The adsorption behavior of chitosan on poly(ethylene terephthalate) (PET) model film surface was studied using the quartz crystal microbalance (QCM) technique. QCM with a dissipation unit (QCM-D) represents a very sensitive technique for adsorption studies at the solid/liquid interface in situ, with capability of detecting a submonolayer of adsorbate on the quartz crystal surface. Chitosan as well as PET were chosen for this study due to their promising biocompatible properties and numerous possibilities to be used in biomedical applications. As a first step, PET foils were activated by alkaline hydrolysis in order to increase their hydrophilicity. Model thin films were prepared from PET foils by the spin coating technique. The chemical composition of the obtained model PET films was analyzed using X-ray photoelectron spectroscopy (XPS) and their morphology was characterized by atomic force microscopy (AFM). Furthermore, the adsorption behavior of chitosan on these activated PET films and the influence of adsorption parameters (pH, ionic strength and chitosan solution concentration) were investigated in detail. Additionally, the surface chemistry and morphology of the PET films and the chitosan coated PET films were analyzed with XPS and AFM.     

聚对苯二甲酸乙二醇酯水解酶检测方法的研究进展

聚对苯二甲酸乙二醇酯(polyethylene terephthalate,PET)是应用最广泛的合成聚酯之一。由于PET不易降解,在环境中积累,对陆地、水生生态系统以及人类健康构成严重威胁。基于生物酶催化的生物降解策略为PET回收利用提供了一种绿色途径,在过去20年间,已发现了多种PET水解酶,并通过蛋白质工程等手段来改善这些酶的降解性能,但是目前仍未找到适合大规模工业应用的PET水解酶。利用传统的检测方法筛选PET水解酶是一个缓慢而复杂的过程。为了促进PET酶法回收的工业化应用,需要研发高效的检测方法。近年来,研究人员开发了多种表征PET水解酶的分析方法。本文总结了可用于筛选PET水解酶的检测方法,如高效液相色谱法、紫外吸光度法和荧光激活液滴分选法等,并对其在筛选PET水解酶的应用方面进行了展望。     

Role of PET/CT in diagnosis and treatment of breast cancer -- review of present knowledge and perspectives for future research

Positron emission tomography (PET) has revolutionized the diagnostic opportunities of malignances, however, it has still a controversial role at some conditions in the management of breast cancer. The article compares PET alone and PET/CT. We review the latest trends of using PET or PET/CT for diagnosis, staging, evaluation of the primary tumor and regional lymph node status, as well as early detection of recurrence and distant lesions. PET/CT provides new methods of assessment of early chemo/endocrine therapy response of locally advanced breast cancer. We discuss the development of new radiotracers and their value in predicting treatment response, identifying tumor subtypes and finding new therapeutic targets by them.     

Thermostability enhancement of polyethylene terephthalate degrading PETase using self- and nonself-ligating protein scaffolding approaches

Polyethylene terephthalate (PET) hydrolase enzymes show promise for enzymatic PET degradation and green recycling of single-use PET vessels representing a major source of global pollution. Their full potential can be unlocked with enzyme engineering to render activities on recalcitrant PET substrates commensurate with cost-effective recycling at scale. Thermostability is a highly desirable property in industrial enzymes, often imparting increased robustness and significantly reducing quantities required. To date, most engineered PET hydrolases show improved thermostability over their parental enzymes. Here, we report engineered thermostable variants of Ideonella sakaiensis PET hydrolase enzyme (IsPETase) developed using two scaffolding strategies. The first employed SpyCatcher-SpyTag technology to covalently cyclize IsPETase, resulting in increased thermostability that was concomitant with reduced turnover of PET substrates compared to native IsPETase. The second approach using a GFP-nanobody fusion protein (vGFP) as a scaffold yielded a construct with a melting temperature of 80°C. This was further increased to 85°C when a thermostable PETase variant (FAST PETase) was scaffolded into vGFP, the highest reported so far for an engineered PET hydrolase derived from IsPETase. Thermostability enhancement using the vGFP scaffold did not compromise activity on PET compared to IsPETase. These contrasting results highlight potential topological and dynamic constraints imposed by scaffold choice as determinants of enzyme activity.     

Small animal PET imaging

Positron emission tomography (PET) is well established as an important research and clinical molecular imaging modality. Although the size differences between humans and rodents create formidable challenges for the application of PET imaging in small animals, advances in technology over the past several years have enabled the translation of this imaging modality to preclinical applications. In this article we discuss the basic principles of PET instrumentation and radiopharmaceuticals, and examine the key factors responsible for the qualitative and quantitative imaging capabilities of small animal PET systems. We describe the criteria that PET imaging agents must meet, and provide examples of small animal PET imaging to give the reader a broad perspective on the capabilities and limitations of this evolving technology. A crucial driver for future advances in PET imaging is the availability of molecular imaging probes labeled with positron-emitting radionuclides. The strong translational science potential of small animal and human PET holds great promise to dramatically advance our understanding of human disease. The assessment of molecular and functional processes using imaging agents as either direct or surrogate biomarkers will ultimately enable the characterization of disease expression in individual patients and thus facilitate tailored treatment plans that can be monitored for their effectiveness in each subject.     

TEP/TDM multi-phase : revue de la littérature

This article reviews the literature of studies that have used multiple-time or later PET image acquisitions mainly with 18F-FDG, for the characterization of solid cancers, their staging or as a prognostic tool. The performances of these PET multiphase acquisitions are presented by organ. References from this literature review were searched using Medline and Google Scholar. Only articles in French and English were selected.     

Photosynthesis-Inhibiting efficiency of 4-chloro-2-(chlorophenylcarbamoyl)phenyl alkylcarbamates

A series of photosynthetic electron transport (PET) inhibitors from the group of salicylanilide alkylcarbamates was investigated. The compounds were analyzed using RP-HPLC to determine lipophilicity, and their PET inhibition was determined in spinach (Spinacia oleracea L.) chloroplasts. The site of action of the studied compounds is situated at the donor site of photosystem 2 (PS 2). Compounds substituted by chlorine in C′-3 and C′-4 of the aniline ring and the optimal length of the alkyl chain pentyl-heptyl in the carbamate moiety provided the most active PET inhibitors (IC₅₀ inhibition <10 μmol/L). Disubstitution in C′-3,4 by chlorine caused significant PET inhibiting activity decrease. Nevertheless, for all three series of C′-3, C′-4, C′-3,4 compounds, the dependence of PET activity on lipophilicity showed to be quasi-parabolic.     

Highly diverged homologs of Saccharomyces cerevisiae mitochondrial mRNA-specific translational activators have orthologous functions in other budding yeasts

Translation of mitochondrially coded mRNAs in Saccharomyces cerevisiae depends on membrane-bound mRNA-specific activator proteins, whose targets lie in the mRNA 5'-untranslated leaders (5'-UTLs). In at least some cases, the activators function to localize translation of hydrophobic proteins on the inner membrane and are rate limiting for gene expression. We searched unsuccessfully in divergent budding yeasts for orthologs of the COX2- and COX3-specific translational activator genes, PET111, PET54, PET122, and PET494, by direct complementation. However, by screening for complementation of mutations in genes adjacent to the PET genes in S. cerevisiae, we obtained chromosomal segments containing highly diverged homologs of PET111 and PET122 from Saccharomyces kluyveri and of PET111 from Kluyveromyces lactis. All three of these genes failed to function in S. cerevisiae. We also found that the 5'-UTLs of the COX2 and COX3 mRNAs of S. kluyveri and K. lactis have little similarity to each other or to those of S. cerevisiae. To determine whether the PET111 and PET122 homologs carry out orthologous functions, we deleted them from the S. kluyveri genome and deleted PET111 from the K. lactis genome. The pet111 mutations in both species prevented COX2 translation, and the S. kluyveri pet122 mutation prevented COX3 translation. Thus, while the sequences of these translational activator proteins and their 5'-UTL targets are highly diverged, their mRNA-specific functions are orthologous.     

聚对苯二甲酸乙二醇酯(PET)降解酶的研究进展

聚对苯二甲酸乙二醇酯(Polyethylene terephthalate,PET)因其优越的物理化学性质,在各个领域尤其在包装产业得到了广泛的应用.然而,由于使用后的PET处置不当,对生态环境造成了严重威胁.目前生物降解尤其是酶促降解已成为极具可行性且环境友好的PET处理方式.本文集中梳理和总结了近年来已报道的PET...     

一株嗜热聚对苯二甲酸乙二醇酯降解菌的分离及其降解特性解析北大核心

【目的】大量聚对苯二甲酸乙二醇酯(polyethylene terephthalate,PET)塑料作为废弃物被丢弃,严重危害生态健康。针对嗜热PET降解菌缺乏这一情况,本研究旨在获得能够降解PET的嗜热菌,并阐述其降解机制。【方法】采集云南腾冲热泉中的废弃PET瓶,分析其表面生物膜的微生物群落多样性,从中筛选能够以PET为营养源生长的嗜热菌,并基于16S rRNA基因序列加以鉴定;以菌株的定殖能力与生长曲线为指标,优选出降解能力较强的降解菌,并测定其最适pH、温度和NaCl浓度;降解能力较强的降解菌分别作用于PET及PET中间体双(羟乙基)对苯二甲酸酯[bis(hydroxyethyl)terephthalate,BHET]和对苯二甲酸单(2-羟乙基)酯[mono(2-hydroxyethyl)terephthalate,MHET],测定产物生成量与降解率;通过观察PET膜表面微观结构、活菌数、酯酶活性等探究降解菌与PET的互作过程。【结果】废弃PET瓶表面生物膜中的微生物群落多样性低;从生物膜中筛选出5株能够以PET为营养源生长的嗜热菌;其中,菌株JQ3以PET为唯一碳源生长最佳,作为降解能力较强的降解菌,被鉴定为嗜热淀粉芽孢杆菌(Bacillus thermoamylovorans),其最适生长pH为7.0、最适生长温度为50℃、最适生长NaCl浓度为0.5%;菌株JQ3以0.043 mg PET/d的速率降解PET,对苯二甲酸(terephthalic acid,TPA)产量在第7天达到峰值45.2 mmol/L;菌株JQ3对PET中间体降解效率显著,6 h可降解85.9%的BHET,60 h可降解50.1%的MHET。菌株JQ3能够定殖于PET表面并形成生物膜,侵蚀PET并造成开裂和剥落。【结论】B.thermoamylovorans JQ3作为一株嗜热PET降解菌,能够高温(60℃)降解PET及其中间体,为实现PET的有效降解提供了新策略。     

Analysis of variance in neuroreceptor ligand imaging studies

Radioligand positron emission tomography (PET) with dual scan paradigms can provide valuable insight into changes in synaptic neurotransmitter concentration due to experimental manipulation. The residual t-test has been utilized to improve the sensitivity of the t-test in PET studies. However, no further development of statistical tests using residuals has been proposed so far to be applied in cases when there are more than two conditions. Here, we propose the residual f-test, a one-way analysis of variance (ANOVA), and examine its feasibility using simulated [(11)C]raclopride PET data. We also re-visit data from our previously published [(11)C]raclopride PET study, in which 10 individuals underwent three PET scans under different conditions. We found that the residual f-test is superior in terms of sensitivity than the conventional f-test while still controlling for type 1 error. The test will therefore allow us to reliably test hypotheses in the smaller sample sizes often used in explorative PET studies.     

Apport de la tomographie par émission de positons dans les tumeurs endocrines digestives : choix du traceur

Digestive endocrine tumors represent a heterogeneous group of neoplasm sharing common characteristics such as their high density of peptide receptors, their ability to take up amino acids and decarboxylate them into biogenic amines and their low glycolytic activity. These features are used for nuclear imaging targeting. To date, somatostatin receptor scintigraphy is considered the “gold standard” imaging procedure of well-differentiated tumors. Despite the significant contribution of SPECT/CT, the use of positron emission tomography imaging (PET) is growing rapidly. Three PET imaging modalities are currently available: 68Ga-labeled somatostatin analogs PET, 18F-dihydroxyphenylalanine PET (¹⁸F-DOPA) and 18F-deoxyglucose PET (¹⁸F-FDG). This article focuses on the current targets of molecular imaging and highlights the potential clinical applications of new targets.     

Therapy region monitoring based on PET using 478 keV single prompt gamma ray during BNCT: A Monte Carlo simulation study

We confirmed the feasibility of using our proposed system to extract two different kinds of functional images from a positron emission tomography (PET) module by using an insertable collimator during boron neutron capture therapy (BNCT). Coincidence events from a tumor region that included boron particles were identified by a PET scanner before BNCT; subsequently, the prompt gamma ray events from the same tumor region were collected after exposure to an external neutron beam through an insertable collimator on the PET detector. Five tumor regions that contained boron particles and were located in the water phantom and in the BNCT system with the PET module were simulated with Monte Carlo simulation code. The acquired images were quantitatively analyzed. Based on the receiver operating characteristic (ROC) curves in the five boron regions, A, B, C, D, and E, the PET and single-photon images were 10.2%, 11.7%, 8.2% (center region), 12.6%, and 10.5%, respectively. We were able to acquire simultaneously PET and single prompt photon images for tumor regions monitoring by using an insertable collimator without any additional isotopes.     

Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales

We have designed new nanoprobes applicable for both positron emission tomography (PET) and optical fluorescence in vivo imaging. Fluorine-18, which is commonly used for clinical imaging, has been coupled to phospholipid quantum dot (QD) micelles. This probe was injected in mice and we demonstrated that its dynamic quantitative whole body biodistribution and pharmacokinetics could be monitored using PET as well as the kinetics of their cellular uptake using in vivo fibered confocal fluorescence imaging. Phospholipid micelle encapsulation of QDs provides a highly versatile surface chemistry to conjugate multiple chemicals and biomolecules with controlled QD:molecule valency. Here, we show that, in contrast with several previous studies using other QD polymer coatings, these phospholipid QD micelles exhibit long circulation half-time in the bloodstream (on the order of 2 h) and slow uptake by reticulo-endothelial system.     

Synthesis and in vivo evaluation of the biodistribution of a 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical application

Gold nanoparticles (AuNPs) have been extensively used in biological applications because of their biocompatibility, size, and ease of characterization, as well as an extensive knowledge of their surface chemistry. These features make AuNPs readily exploitable for biomedical applications, including drug delivery and novel diagnostic and therapeutic approaches. In a previous work, we studied ex vivo distribution of the conjugate C(AuNP)-LPFFD for its potential uses in the treatment of Alzheimer's disease. In this study, we covalently labeled the conjugate with [(18)F]-fluorobenzoate to study the in vivo distribution of the AuNP by positron emission tomography (PET). After intravenous administration in rat, the highest concentration of the radiolabeled conjugate was found in the bladder and urine with a lower proportion in the intestine, demonstrating progressive accumulation compatible with biliary excretion of the conjugate. The conjugate also accumulated in the liver and spleen. PET imaging allowed us to study the in vivo biodistribution of the AuNPs in a noninvasive and sensitive way using a reduced number of animals. Our results show that AuNPs can be covalently and radioactively labeled for PET biodistribution studies.     

A Recommendation for Revised Dose Calibrator Measurement Procedures for 89Zr and 124I

Because of their chemical properties and multiday half lives, iodine-124 and zirconium-89 are being used in a growing number of PET imaging studies. Some aspects of their quantitation, however, still need attention. For ⁸⁹Zr the PET images should, in principle, be as quantitatively accurate as similarly reconstructed ¹⁸F measurements. We found, however, that images of a 20 cm well calibration phantom containing ⁸⁹Zr underestimated the activity by approximately 10% relative to a dose calibrator measurement (Capintec CRC-15R) using a published calibration setting number of 465. PET images of ¹²⁴I, in contrast, are complicated by the contribution of decays in cascade that add spurious coincident events to the PET data. When these cascade coincidences are properly accounted for, quantitatively accurate images should be possible. We found, however, that even with this correction we still encountered what appeared to be a large variability in the accuracy of the PET images when compared to dose calibrator measurements made using the calibration setting number, 570, recommended by Capintec. We derive new calibration setting numbers for ⁸⁹Zr and ¹²⁴I based on their 511 keV photon peaks as measured on an HPGe detector. The peaks were calibrated relative to an ¹⁸F standard, the activity level of which was precisely measured in a dose calibrator under well-defined measurement conditions. When measuring ⁸⁹Zr on a Capintec CRC-15R we propose the use of calibration setting number 517. And for ¹²⁴I, we recommend the use of a copper filter surrounding the sample and the use of calibration setting number 494. The new dose calibrator measurement procedures we propose will result in more consistent and accurate radioactivity measurements of ⁸⁹Zr and ¹²⁴I. These and other positron emitting radionuclides can be accurately calibrated relative to ¹⁸F based on measurements of their 511 keV peaks and knowledge of their relative positron abundances.     

Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer’s disease

PurposeA standardized method for quantification is required for analyzing PET data, but such standards have not been established for tau PET imaging. The Centiloid scale has recently been proposed as a standard method for quantifying amyloid deposition on PET imaging. Therefore, the present study aimed to apply the Centiloid scale to ¹⁸F-THK5351 PET imaging in Alzheimer’s disease (AD).MethodsWe acquired ¹⁸F-THK5351 PET, ¹¹C-PiB PET, and MR images from 47 cognitively normal (CN) individuals and 28 patients with AD with mild to moderate dementia. PET images were spatially normalized to Montreal Neurological Institute space. The PET signals were then normalized using the signal in the reference volume of interest (VOI). Target VOI for specific ¹⁸F-THK5351 retention in AD was extracted by voxel-wise comparison of PET images between the 47 CN individuals and 16 AD patients with moderate dementia. Scale anchor points were defined by the CN individuals as 0-anchor points and by that of the average of the typical AD patients as 100-anchor points.ResultsSpecific retention of ¹⁸F-THK5351 was predominant in the angular gyrus, inferior temporal cortex, and parieto-occipital regions in patients with AD. Standardized uptake value ratio (SUVR) of 1.227 and 1.797 were defined as 0- and 100-anchor points, respectively. ¹⁸F-THK5351 PET data could be expressed using the Centiloid scale, with the SUVR of the ¹⁸F-THK5351 PET images converted to Centiloid using our VOI, the standard Centiloid reference VOI, and the following equation: Centiloid = 169.0 × SUVR–204.6.ConclusionCentiloid methods can be applied to tau PET imaging using ¹⁸F-THK5351.     

Targeting peptides and positron emission tomography

Biologically active peptides have during the last decades made their way into conventional nuclear medicine diagnosis using single photon emission computed tomography (SPECT) and gamma-camera. Several clinical trails are also investigating the role of radiolabeled peptides for targeting radionuclide therapy. This has raised the question as to whether positron emission tomography (PET) can be used in order to obtain better quantitative information of the peptide distribution in tumor and healthy organs, i.e., to get a better dosimetry. Positron emitting analogs of the therapeutic radionuclides used have been produced and successfully applied in peptide pharmacokinetic measurements with PET. But the recent boom in (18)FDG-PET ((18)FDG = [(18)F]2-deoxy-2-fluoro-D-glucose), and with this a worldwide increasing number of PET systems, has also inspired several research groups to hunt for alternative labels to be used for peptide diagnostics and PET. The rapid kinetic of short peptides agrees well with the short half-lives of standard PET nuclides like (11)C and (18)F. Especially, (18)F appears to be excellent for labeling bioactive peptides due to its favorable physical and nuclear characteristics. However, with present techniques labeling peptides with (18)F is laborious and time-consuming, and is not yet a clinical alternative. Other halogens like (75, 76)Br and (124)I are, from the chemical point of view, easier to apply. But an even better labeling alternative may be positron emitting metal ions like (55)Co, (68)Ga, and (110m)In since they tend to give better intracellular retention and thus a better signal-to-background ratio than the halogen labels. The main drawback with these radionuclides is that they are not readily available. Some of these radionuclides also emit gamma in their decay that may affect the measuring properties of the PET equipment. This article reviews mainly the present situation of production and use of nonconventional positron emitters for peptide labeling.     

PET脑血流量测量方法和临床应用进展

脑血流量测量对于脑血管疾病、脑肿瘤诊断和疗效评估具有重要的临床价值。PET是基于正电子示剂技术无创性、精确测量脑血流量的方法,正日益广泛地应用于临床。按照PET测量脑血流量的方法和使用的正电子示踪剂不同,其测量方法分为平衡法、放射自显影法和动力学方法三种。18O-H2O示踪剂PET测量脑血流量被认为测量脑血流方法的"金标准"。随着PET设备分辨率提高、新的图像重建方法使用和PET与MRI图像融合技术不断成熟,18F-FDG首次通过、采用图像衍生动脉输入函数(imagederived arterial input function,IDAIF)替代动脉抽血样精确测量脑血量方法受到广泛重视,有可能逐步取代高成本的18O-H2O测量脑血流量。PET无创、方便和精确测量脑血流量的方法在临床应使用有助于脑血管性疾病、脑肿瘤和脑退行性病变早期诊断、鉴别诊断和个性化医疗。本文介绍PET脑血流量测量原理、方法和临床应用进展。